Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: Two novel alternatives

FEMS Immunology and Medical Microbiology

Volumn 65, Issue 3, 2012, Pages 399-412

  Fitzgerald Hughes, Deirdre ^a   Devocelle, Marc ^a   Humphreys, Hilary ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

Anti infectives; Antibacterial agents; MRSA; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BAC8C; BACTENECIN; BUFORIN II; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CIPROFLOXACIN; IDR 1; IDR 1002; IMCROPORIN; ISEGANAN; MUCROPORIN; NORFLOXACIN; OMIGANAN; PEXIGANAN; PMX 30063D; SORTASE; SYPHAXIN; TEMPORIN 10A; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BIOSYNTHESIS; DRUG MECHANISM; HOST RESISTANCE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUORUM SENSING;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PEPTIDES, CYCLIC; PORINS; STAPHYLOCOCCAL INFECTIONS; TRANS-ACTIVATORS; VIRULENCE; XANTHOPHYLLS;

EID: 84863994637     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2012.00954.x     Document Type: Article

References (108)

1. Augustin R, Anton-Erxleben F, Jungnickel S, Hemmrich G, Spudy B, Podschun R & Bosch TC (2009) Activity of the novel peptide arminin against multiresistant human pathogens shows the considerable potential of phylogenetically ancient organisms as drug sources. Antimicrob Agents Chemother 53: 5245-5250.
2. Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V & Scalise G (2007) Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 51: 2226-2229.
3. Bals R, Wang X, Zasloff M & Wilson JM (1998) The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. P Natl Acad Sci USA 95: 9541-9546.
4. Baltz RH (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 13: 144-151.
5. Boles BR & Horswill AR (2008) Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 4: e1000052.
6. Bommarius B, Jenssen H, Elliott M, Kindrachuk J, Pasupuleti M, Gieren H, Jaeger KE, Hancock RE & Kalman D (2010) Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 31: 1957-1965.
7. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG & Hancock RE (2005) Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77: 451-459.
8. Bowdish DM, Davidson DJ & Hancock RE (2006) Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol 306: 27-66.
9. Bray BL (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2: 587-593.
10. Chakrapani H, Kalathur RC, Maciag AE, Citro ML, Ji X, Keefer LK & Saavedra JE (2008) Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorg Med Chem 16: 9764-9771.
11. Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML & Hodges RS (2005) Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem 280: 12316-12329.
12. Cheung AL, Bayer AS, Zhang G, Gresham H & Xiong YQ (2004) Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 40: 1-9.
13. Cirioni O, Silvestri C, Ghiselli R, Giacometti A, Orlando F, Mocchegiani F, Chiodi L, Vittoria AD, Saba V & Scalise G (2006) Experimental study on the efficacy of combination of alpha-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides. Peptides 27: 2600-2606.
14. Dai C, Ma Y, Zhao Z, Wang Q, Wu Y, Cao Z & Li W (2008) Mucroporin, the first cationic host defense peptide from the venom of Lychas mucronatus. Antimicrob Agents Chemother 52: 3967-3972.
15. Dathe M, Wieprecht T, Nikolenko H, Handel L, Maloy WL, MacDonald DL, Beyermann M & Bienert M (1997) Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett 403: 208-212.
16. Dauner DG, Nelson RE & Taketa DC (2010) Ceftobiprole: a novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 67: 983-993.
17. Dean SN, Bishop BM & van Hoek ML (2011) Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol 11: 114.
18. Dell'Acqua G, Giacometti A, Cirioni O, Ghiselli R, Saba V, Scalise G, Gov Y & Balaban N (2004) Suppression of drug-resistant Staphylococcal infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide. J Infect Dis 190: 318-320.
19. Dourado FS, Leite JR, Silva LP, Melo JA, Bloch C Jr & Schwartz EF (2007) Antimicrobial peptide from the skin secretion of the frog Leptodactylus syphax. Toxicon 50: 572-580.
20. Ellerby HM, Arap W, Ellerby LM et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
21. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D & Peschel A (2009) The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5: e1000660.
22. Fluit AC, Wielders CL, Verhoef J & Schmitz FJ (2001) Epidemiology and susceptibility of 3, 051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 39: 3727-3732.
23. Fuchs PC, Barry AL & Brown SD (1998) In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother 42: 1213-1216.
24. George EA, Novick RP & Muir TW (2008) Cyclic peptide inhibitors of staphylococcal virulence prepared by Fmoc-based thiolactone peptide synthesis. J Am Chem Soc 130: 4914-4924.
25. Giacometti A, Cirioni O, Del Prete MS, Paggi AM, D'Errico MM & Scalise G (2000) Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. Peptides 21: 1155-1160.
26. Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Licci A, Nadolski P, Riva A, Lukasiak J & Scalise G (2005) In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. Int J Antimicrob Agents 26: 235-240.
27. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T & Peters G (2012) New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39: 96-104.
28. Hadley EB & Hancock RE (2010) Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr Top Med Chem 10: 1872-1881.
29. Hamamoto K, Kida Y, Zhang Y, Shimizu T & Kuwano K (2002) Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 46: 741-749.
30. Hancock RE & Patrzykat A (2002) Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2: 79-83.
31. Hancock RE & Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557.
32. Hartman BJ & Tomasz A (1984) Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 158: 513-516.
33. Hilpert K, Volkmer-Engert R, Walter T & Hancock REW (2005) High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 23: 1008-1012.
34. Hong SY, Oh JE & Lee KH (1999) Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58: 1775-1780.
35. Imura Y, Nishida M, Ogawa Y, Takakura Y & Matsuzaki K (2007) Action mechanism of tachyplesin I and effects of PEGylation. Biochim Biophys Acta 1768: 1160-1169.
36. Jia L, Noker PE, Piazza GA, Leuschner C, Hansel W, Gorman GS, Coward LU & Tomaszewski J (2008) Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate. J Pharm Pharmacol 60: 1441-1448.
37. Jonsson IM, Mazmanian SK, Schneewind O, Bremell T & Tarkowski A (2003) The role of Staphylococcus aureus sortase A and sortase B in murine arthritis. Microbes Infect 5: 775-780.
38. Kahlon AK, Roy S & Sharma A (2010) Molecular docking studies to map the binding site of squalene synthase inhibitors on dehydrosqualene synthase of Staphylococcus aureus. J Biomol Struct Dyn 28: 201-210.
39. Kim JB, Iwamuro S, Knoop FC & Conlon JM (2001) Antimicrobial peptides from the skin of the Japanese mountain brown frog, Rana ornativentris. J Pept Res 58: 349-356.
40. Kubica M, Guzik K, Koziel J et al. (2008) A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS ONE 3: e1409.
41. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y & Otto M (2009) Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. P Natl Acad Sci USA 106: 5883-5888.
42. Li Q, Zhou Y, Dong K & Guo X (2010a) Potential therapeutic efficacy of a bactericidal-immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus skin infection. Appl Microbiol Biotechnol 86: 305-309.
43. Li Q, Zhou Y, Dong K & Guo X (2010b) Potential therapeutic efficacy of a bactericidal-immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus skin infection. Appl Microbiol Biotechnol 86: 305-309.
44. Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J & Nizet V (2005) Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 202: 209-215.
45. Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH & Oldfield E (2008) A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319: 1391-1394.
46. Liu C, Bayer A, Cosgrove SE et al. (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis 52: e18-e55.
47. Lyon GJ, Mayville P, Muir T & Novick RP (2000) Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. PNAS 97: 13330-13335.
48. Mader JS & Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15: 933-946.
49. Maresso AW, Wu R, Kern JW, Zhang R, Janik D, Missiakas DM, Duban ME, Joachimiak A & Schneewind O (2007) Activation of inhibitors by sortase triggers irreversible modification of the active site. J Biol Chem 282: 23129-23139.
50. Marks AJ, Cooper MS, Anderson RJ et al. (2005) Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res 65: 2373-2377.
51. Mazmanian SK, Liu G, Ton-That H & Schneewind O (1999) Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285: 760-763.
52. Mazmanian SK, Liu G, Jensen ER, Lenoy E & Schneewind O (2000) Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. P Natl Acad Sci USA 97: 5510-5515.
53. Mazmanian SK, Ton-That H, Su K & Schneewind O (2002) An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. P Natl Acad Sci USA 99: 2293-2298.
54. Mookherjee N, Brown KL, Bowdish DM et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176: 2455-2464.
55. Mosca DA, Hurst MA, So W, Viajar BS, Fujii CA & Falla TJ (2000) IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob Agents Chemother 44: 1803-1808.
56. Mygind PH, Fischer RL, Schnorr KM et al. (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437: 975-980.
57. Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW & Grote JJ (2006) Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27: 649-660.
58. Nielsen A, Nielsen KF, Frees D, Larsen TO & Ingmer H (2010) Method for screening compounds that influence virulence gene expression in Staphylococcus aureus. Antimicrob Agents Chemother 54: 509-512.
59. Nijnik A, Madera L, Ma S et al. (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184: 2539-2550.
60. Novick RP (2003) Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 48: 1429-1449.
61. Oh KB, Kim SH, Lee J, Cho WJ, Lee T & Kim S (2004) Discovery of diarylacrylonitriles as a novel series of small molecule sortase A inhibitors. J Med Chem 47: 2418-2421.
62. Oh KB, Nam KW, Ahn H, Shin J, Kim S & Mar W (2010) Therapeutic effect of (Z)-3-(2, 5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) against Staphylococcus aureus infection in a murine model. Biochem Biophys Res Commun 396: 440-444.
63. O'Neill E, Pozzi C, Houston P, Humphreys H, Robinson DA, Loughman A, Foster TJ & O'Gara JP (2008) A novel Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol 190: 3835-3850.
64. Panyutich AV, Voitenok NN, Lehrer RI & Ganz T (1991) An enzyme immunoassay for human defensins. J Immunol Methods 141: 149-155.
65. Park CB, Kim HS & Kim SC (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244: 253-257.
66. Peschel A, Jack RW, Otto M et al. (2001) Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 193: 1067-1076.
67. Prabhu K, Rao S & Rao V (2011) Inducible Clindamycin Resistance in Staphylococcus aureus Isolated from Clinical Samples. J Lab Physicians 3: 25-27.
68. Qazi S, Middleton B, Muharram SH, Cockayne A, Hill P, O'Shea P, Chhabra SR, Cámara M & Williams P (2006) N-acylhomoserine lactones antagonize virulence gene expression and quorum sensing in Staphylococcus aureus. Infect Immun 74: 910-919.
69. Reynolds PE & Brown DF (1985) Penicillin-binding proteins of beta-lactam-resistant strains of Staphylococcus aureus. Effect of growth conditions. FEBS Lett 192: 28-32.
70. Ribeiro PD, Ribeiro OD, Marcolan AM & Medina-Acosta E (2003) Treatment efficacy of the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus sepsis: a histopathological assessment. Peptides 24: 1829-1836.
71. Rotem S & Mor A (2009) Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta 1788: 1582-1592.
72. Ruiz de Gopegui E, Juan C, Zamorano L, Perez JL & Oliver A (2012) Transferable multidrug resistance plasmid carrying cfr associated with tet(L), ant(4′)-Ia and dfrK genes from a clinical methicillin-resistant Staphylococcus aureus ST125 strain. Antimicrob Agents Chemother 56: 2139-2142.
73. Sader HS, Fedler KA, Rennie RP, Stevens S & Jones RN (2004) Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 48: 3112-3118.
74. Sadler K, Eom KD, Yang JL, Dimitrova Y & Tam JP (2002) Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 41: 14150-14157.
75. Sakai K, Koyama N, Fukuda T, Mori Y, Onaka H & Tomoda H (2012) Search method for inhibitors of Staphyloxanthin production by methicillin-resistant Staphylococcus aureus. Biol Pharm Bull 35: 48-53.
76. Scott MG, Dullaghan E, Mookherjee N et al. (2007) An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 25: 465-472.
77. Sharma A, Slugg PH, Hammett JL & Jusko WJ (1998a) Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol 38: 1116-1121.
78. Sharma A, Slugg PH, Hammett JL & Jusko WJ (1998b) Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res 15: 1782-1786.
79. Shaw LN, Jonsson IM, Singh VK, Tarkowski A & Stewart GC (2007) Inactivation of traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus aureus. Infect Immun 75: 4519-4527.
80. Shimazaki K, Nam MS, Harakawa S, Tanaka T, Omata Y, Saito A, Kumura H, Mikawa K, Igarashi I & Suzuki N (1996) Monoclonal antibody against bovine Lactoferricin and its epitopic site. J Vet Med Sci 58: 1227-1229.
81. Simonetti O, Cirioni O, Ghiselli R et al. (2008) RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52: 2205-2211.
82. Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI & Kagan BL (1999) Membrane channel formation by antimicrobial protegrins. Biochim Biophys Acta 1420: 23-29.
83. Song S, Liu D, Peng J, Deng H, Guo Y, Xu LX, Miller AD & Xu Y (2009a) Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 23: 1396-1404.
84. Song Y, Lin FY, Yin F et al. (2009b) Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem 52: 976-988.
85. Song Y, Liu CI, Lin FY et al. (2009c) Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem 52: 3869-3880.
86. Sorensen O, Cowland JB, Askaa J & Borregaard N (1997) An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 206: 53-59.
87. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J & Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46: 193-200.
88. Spindler EC, Hale JD, Giddings TH Jr, Hancock RE & Gill RT (2011) Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c. Antimicrob Agents Chemother 55: 1706-1716.
89. Stromstedt AA, Pasupuleti M, Schmidtchen A & Malmsten M (2009) Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob Agents Chemother 53: 593-602.
90. Sun F, Cho H, Jeong DW, Li C, He C & Bae T (2011) Aureusimines in Staphylococcus aureus are not involved in virulence. PLoS ONE 5: e15703.
91. Suree N, Yi SW, Thieu W, Marohn M, Damoiseaux R, Chan A, Jung ME & Clubb RT (2009) Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg Med Chem 17: 7174-7185.
92. Szynol A, de Haard JJ, Veerman EC, de Soet JJ & van Nieuw Amerongen AV (2006) Design of a peptibody consisting of the antimicrobial peptide dhvar5 and a llama variable heavy-chain antibody fragment. Chem Biol Drug Des 67: 425-431.
93. Tew GN, Clements D, Tang H, Arnt L & Scott RW (2006) Antimicrobial activity of an abiotic host defense peptide mimic. Biochim Biophys Acta 1758: 1387-1392.
94. Tomasinsig L, Morgera F, Antcheva N, Pacor S, Skerlavaj B, Zanetti M & Tossi A (2009) Structure dependence of biological activities for primate cathelicidins. J Pept Sci 15: 576-582.
95. Turner-Brannen E, Choi KY, Lippert DN, Cortens JP, Hancock RE, El-Gabalawy H & Mookherjee N (2011) Modulation of interleukin-1beta-induced inflammatory responses by a synthetic cationic innate defence regulator peptide, IDR-1002, in synovial fibroblasts. Arthritis Res Ther 13: R129.
96. Voyich JM, Braughton KR, Sturdevant DE et al. (2005) Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 175: 3907-3919.
97. Weiss WJ, Lenoy E, Murphy T, Tardio L, Burgio P, Projan SJ, Schneewind O & Alksne L (2004) Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection. J Antimicrob Chemother 53: 480-486.
98. Westerhoff HV, Juretić D, Hendler RW & Zasloff M (1989) Magainins and the disruption of membrane-linked free-energy transduction. P Natl Acad Sci USA 86: 6597-6601.
99. Wright JS III, Jin R & Novick RP (2005) Transient interference with staphylococcal quorum sensing blocks abscess formation. P Natl Acad Sci USA 102: 1691-1696.
100. Wyatt MA, Wang W, Roux CM, Beasley FC, Heinrichs DE, Dunman PM & Magarvey NA (2010) Staphylococcus aureus nonribosomal peptide secondary metabolites regulate virulence. Science 329: 294-296.
101. Yang D & Oppenheim JJ (2004) Multiple functions of antimicrobial peptides in host immunity. Mammalian Host Defence Peptides (Hancock REW & Devine D, eds), pp. 39-68. Cambridge Univ. Press, New York, AMCM, Series.
102. Yeaman MR, Bayer AS, Koo SP, Foss W & Sullam PM (1998) Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest 101: 178-187.
103. Yeung AT, Gellatly SL & Hancock RE (2011) Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 68: 2161-2176.
104. Yoon EJ, Kwon AR, Min YH & Choi EC (2008) Foggy D-shaped zone of inhibition in Staphylococcus aureus owing to a dual character of both inducible and constitutive resistance to macrolide-lincosamide-streptogramin B. J Antimicrob Chemother 61: 533-540.
105. Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM & Karlowsky JA (2008) Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 9: 245-254.
106. Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ & Karlowsky JA (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70: 859-886.
107. Zhang L & Falla TJ (2006) Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother 7: 653-663.
108. Zhao Z, Ma Y, Dai C, Zhao R, Li S, Wu Y, Cao Z & Li W (2009) Imcroporin, a new cationic antimicrobial peptide from the venom of the scorpion Isometrus maculates. Antimicrob Agents Chemother 53: 3472-3477.